Moving Toward a Personalized Approach to Screening and Management

COLORECTAL CANCER VIRTUAL EDUCATION SUMMIT
Moving Toward a Personalized Approach to Screening and Management

Presented by the Northwestern University Feinberg School of Medicine

ACKNOWLEDGEMENT
This activity is supported by an educational grant from Ferring Pharmaceuticals, Inc. and Lilly.
For further information concerning Lilly grant funding visit www.lillygrantoffice.com

TUITION
Complimentary

ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Northwestern University Feinberg School of Medicine and PlatformQ LLC. Northwestern University Feinberg School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENTS
Live Activity
The Northwestern University Feinberg School of Medicine designates this live activity for a maximum of 2 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Enduring Material
The Northwestern University Feinberg School of Medicine designates this enduring material for a maximum of 2 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

OTHER CREDITS
American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 2 hours of Category 1 credit for completing these programs.

DATE OF RELEASE/EXPIRATION
Live Activity
Thursday, January 30, 2014 from 10:00AM to 12:00PM ET
Enduring Material
January 30, 2014 to June 30, 2014

LEARNING OBJECTIVES
At the conclusion of this activity, participants will be able to:

Characterize the data supporting the use of screening and understand the importance of increasing the rate colorectal screening in reducing the incidence of these cancers.
Be informed on the role of neoadjuvant and adjuvant therapy in the management of colorectal cancer and prepared to implement strategies in patients.
Implement complex and effective management strategies for colorectal cancer, incorporating the latest data on targeted biologics and other new therapies in order to optimize outcomes in patients.

TARGET AUDIENCE
This activity is intended for oncologists, radiation oncologists, surgical oncologists, gastroenterologists, pathologists, oncology nurses, advanced practice nurses, and other healthcare professionals, who care for patients with colorectal cancer.

ESTIMATED TIME TO COMPLETE
The activity consists of two sessions, which should take approximately 2.0 hours to complete.

METHOD OF PARTICIPATION
There are no fees to participate in this activity. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. It is estimate that each module will take approximately 1 hour to complete. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FACULTY DISCLOSURE
In accordance with ACCME Standards for Commercial Support of Continuing Medical Education and the Feinberg School of Medicine's (FSM) disclosure policy for CME activities, all individuals who contribute to the content or the identification / resolution of potential conflicts of interest must disclose any relationship they may have with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients within the preceding 12 months of the activity. Such disclosure is intended to provide participants with sufficient information to evaluate whether any given presentation has been influence by the faculty's relationships(s) or financial interest with said companies.

Presenters: Disclosures:
Al B. Benson III, MD, FACP Research: Amgen, Bayer Healthcare, Genentech, Gilead, Astellas, Novartis, Advanced Accelerator Applications SA
Advisory Board: Precision Therapeutics, Inc., Eli Lilly and Company, Spectrum Pharmaceuticals, Bristol Meyers Squibb, McKinsey, Cleveland Biolabs, Gilead, Bayer Healthcare, Genentech
Consultant: Genomic Health, Inc., National Cancer Institute
DMC: Amgen, Alchemia, Infinity
M. Rosario Ferreira, MD Has nothing to disclose.
John L. Marshall, MD Speaker: Amgen, Genentech, Bayer/Onyx
Research: Amgen, Genentech, Bayer/Onyx
Brandon G. Smaglo, MD Has nothing to disclose.
FSM's CME Leadership  
John X. Thomas, Jr., PhD, Sr. Associate Dean for Medical Education Has nothing to disclose.
Genevieve Napier, CME Director Has nothing to disclose.
Jennifer Banys and Tara Scavelli, CME Project Specialists Have nothing to disclose.
PlatformQ Health, Inc  
Deborah Sharkey, Associate Program Manager Has nothing to disclose.
Alyce Kuklinski, NP, RN, Senior Medical Director Has nothing to disclose.

CONTACT INFORMATION
Please send all inquiries to: Northwestern University Feinberg School of Medicine, Office of Continuing Medical Education, by phone: 312-503-8533312-503-8533 or email: nums-cme@northwestern.edu.

For issues with your CME Certificate, please contact OMedLive at 877-394-1306877-394-1306 or at Support@OMedLive.com

Advances in Prostate Cancer Screening & Management

ACKNOWLEDGEMENT
This activity is supported by educational grants from Bayer Healthcare Pharmaceuticals, Inc., Abbvie Inc., Millennium: The Takeda Oncology Company and Janssen Biotech, Inc.

TUITION
Complimentary

ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Northwestern University Feinberg School of Medicine and PlatformQ LLC. Northwestern University Feinberg School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENTS
The Northwestern University Feinberg School of Medicine designates this educational activity for a maximum of 5 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

OTHER CREDITS
American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 5 hours of Category 1 credit for completing these programs.

DATE OF RELEASE/EXPIRATION
Live sessions will be available: Thursday, January 9, 2014 from 10:00AM to 3:00PM ET

LEARNING OBJECTIVES
At the conclusion of this activity, participants will be able to:

Compare and contrast prostate cancer screening and diagnosis using traditional PSA testing and other biomarker-based testing.
Summarize current strategies for ADT in men with advance prostate cancer.
Demonstrate application of guideline recommendations to the management of a patient receiving ADT.
Summarize the key therapeutic advances for the treatment of mCRPC.
Discuss evidence-based approach to treatment selection and strategies for the optimal management of mCRPC, including treatment initiation, combinations and sequencing.
Summarize the evidence, benefits and limitations of currently available treatment options for the management of skeletal related events in patients with prostate cancer.
Summarize strategies to minimize or treat adverse effects and complications associated with prostate cancer management.

TARGET AUDIENCE
This activity is intended for oncologists, urologists, oncology nurses and other clinicians involved with the diagnosis and management of patients with prostate cancer.

ESTIMATED TIME TO COMPLETE
The activity consists of four sessions, which should take approximately 5.0 hours to complete.

METHOD OF PARTICIPATION
There are no fees to participate in this activity. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. It is estimate that each module will take approximately 1 hour to complete. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FACULTY DISCLOSURE
In accordance with ACCME Standards for Commercial Support of Continuing Medical Education and the Feinberg School of Medicine's (FSM) disclosure policy for CME activities, all individuals who contribute to the content or the identification / resolution of potential conflicts of interest must disclose any relationship they may have with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients within the preceding 12 months of the activity. Such disclosure is intended to provide participants with sufficient information to evaluate whether any given presentation has been influence by the faculty's relationships(s) or financial interest with said companies.

Faculty disclosures will come prior to event.

CONTACT INFORMATION
Please send all inquiries to: Northwestern University Feinberg School of Medicine, Office of Continuing Medical Education, by phone: 312-503-8533312-503-8533 or email: nums-cme@northwestern.edu.

Managing the Patient with BPH-LUTS and Erectile Dysfunction

ACKNOWLEDGEMENT
This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com

TUITION
Complimentary

ACCREDITATION STATEMENT
The activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Albert Einstein College of Medicine of Yeshiva University and Montefiore Medical Center and PlatformQ LLC. The Albert Einstein College of Medicine of Yeshiva University is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENTS
The Albert Einstein College of Medicine of Yeshiva University designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

OTHER CREDITS
American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 1.0 hours of Category 1 credit for completing these programs.

DATE OF RELEASE/EXPIRATION
Live Activity
Thursday, December 19, 2013 from 10:00 AM to 11:00 AM ET


LEARNING OBJECTIVES
At the conclusion of this activity, participants will be able to:

Outline the pathophysiology of BPH-LUTS, and assess patients with BPH-LUTS for symptom severity, risk of disease progression, comorbidities, and effects on function and quality of life
Compare the mechanisms of action, risk/benefit profiles and efficacy of α1-adrenergic receptor blockers, 5α-reductase inhibitors, and phosphodiesterase-5 inhibitors in the treatment of BPH-LUTS with and without erectile dysfunction
Initiate, monitor and optimize a treatment plan for the patient with BPH-LUTS that includes both pharmacologic and behavioral interventions, and that takes into consideration common comorbidities, risk of progression and patient preferences in order to optimize treatment outcomes

INTENDED AUDIENCE
This activity is intended for urologists, internists, advanced practice nurses, physician assistants, pharmacists, nurses and other clinicians involved with the diagnosis and treatment of patients with BPH-LUTS and erectile dysfunction.

ESTIMATED TIME TO COMPLETE
The activity consists of three sessions, each of which should take approximately 1.0 hours to complete.

METHOD OF PARTICIPATION
There are no fees to participate in this activity. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. It is estimated that each module will take approximately 1 hour to complete. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FACULTY DISCLOSURE
The "Conflict of Interest Disclosure Policy" of Albert Einstein College of Medicine requires that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience any relationship(s) with a pharmaceutical or equipment company. Any presenter whose disclosed relationships prove to create a conflict of interest, with regard to their contribution to the activity, will not be permitted to present.

The Albert Einstein College of Medicine also requires that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience when discussing any unlabeled or investigational use of any commercial product, or device, not yet approved for use in the United States.

Faculty Disclousers will come prior to the live event date

CONTACT INFORMATION
Please send all inquiries to: Montefiore Medical Center, CCME, 3301 Bainbridge Avenue, Bronx, New York 10467, or via phone at (718) 920-6674(718) 920-6674, or via fax to (718) 798-2336, or via email to cme@montefiore.org.

For issues with your CME Certificate, please contact OMedLive at 877-394-1306877-394-1306 or at Support@OMedLive.com

Improving the Recognition and Management of Breakthrough Cancer Pain

ACKNOWLEDGEMENT
This activity is supported by educational grants by Teva Pharmaceuticals.

TUITION
Complimentary

ACCREDITATION STATEMENT
The activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Albert Einstein College of Medicine of Yeshiva University and Montefiore Medical Center and PlatformQ LLC. The Albert Einstein College of Medicine of Yeshiva University is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENTS
The Albert Einstein College of Medicine of Yeshiva University designates this live internet activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

OTHER CREDITS
American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 1.0 hours of Category 1 credit for completing these programs.

DATE OF RELEASE/EXPIRATION
Live Internet Activity
Friday, December 4, 2013 from 1:00 PM to 2:00 PM ET
Enduring Material
The enduring material will be available from December 4, 2013 to June 4, 2014

LEARNING OBJECTIVES
At the conclusion of this activity, participants will be able to:

Characterize the features of BTP, differentiate BTP from baseline chronic pain and assess BTP in patients with cancer.
Establish a management strategy for cancer patients with BTP.
Establish safe prescribing practices for the use of opioid therapies in the treatment of cancer-related BTP.

INTENDED AUDIENCE
This activity is intended for cancer pain specialists, oncologists, palliative care specialists, pain management specialists, oncology nurses, nurse practitioners, physician assistants, nurses, pharmacists, rehabilitative medicine specialists and other clinicians involved with the diagnosis and treatment of breakthrough cancer pain.

ESTIMATED TIME TO COMPLETE
The activity consists of one session, which should take approximately 1 hour to complete.

METHOD OF PARTICIPATION
There are no fees to participate in this activity. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. It is estimated that each module will take approximately 1 hour to complete. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FACULTY DISCLOSURE
The "Conflict of Interest Disclosure Policy" of Albert Einstein College of Medicine requires that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience any relationship(s) with a pharmaceutical or equipment company. Any presenter whose disclosed relationships prove to create a conflict of interest, with regard to their contribution to the activity, will not be permitted to present.

The Albert Einstein College of Medicine also requires that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience when discussing any unlabeled or investigational use of any commercial product, or device, not yet approved for use in the United States.

Presenters: Disclosures:
Dermot R. Fitzgibbon, MD Has nothing to disclose
Kelly Pollak, MD Has nothing to disclose
Einstein-Montefiore Center for Continuing Medical Education The Center for Continuing Medical Education (CCME) staff at Albert Einstein College of Medicine of Yeshiva University has no disclosures to report.
Naum Shaparin, MD Speaker's Bureau: Cadence Pharmaceuticals, Salix Pharmaceuticals
PlatformQ Health, Inc  
Randi O'Hara, Senior Program Manager Has nothing to disclose.
Alyce Kuklinski, NP, RN, Senior Medical Director Has nothing to disclose.

CONTACT INFORMATION
Please send all inquiries to: Montefiore Medical Center, CCME, 3301 Bainbridge Avenue, Bronx, New York 10467, or via phone at (718) 920-6674(718) 920-6674, or via fax to (718) 798-2336, or via email to cme@montefiore.org.

For issues with your CME Certificate, please contact OMedLive at 877-394-1306877-394-1306 or at Support@OMedLive.com

The Changing Landscape of Hemophilia Management

ACKNOWLEDGEMENT
This activity is supported by educational grants from CSL Behring LLC, Baxter Healthcare, and Grifols.

TUITION
Complimentary

ACCREDITATION STATEMENT
The activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Albert Einstein College of Medicine of Yeshiva University and Montefiore Medical Center and PlatformQ LLC. The Albert Einstein College of Medicine of Yeshiva University is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENTS
The Albert Einstein College of Medicine of Yeshiva University designates this enduring material for a maximum of 3.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

OTHER CREDITS
American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 3.0 hours of Category 1 credit for completing these programs.

DATE OF RELEASE/EXPIRATION
Live Activity
Thursday, October 24, 2013 from 10:00 AM to 1:00 PM ET
Enduring Material
The enduring material will be available from October 24, 2013 to April 24, 2014

LEARNING OBJECTIVES
At the conclusion of this activity, participants will be able to:

Summarize new and emerging therapies for the treatment of patients with hemophilia, including gene therapy.
Identify key barriers to adherence to prophylaxis in hemophilia.
Describe strategies to overcoming prophylaxis adherence barriers.
Discuss the complications and comorbidities associated with hemophilia and the management within the context of hemophilia.

INTENDED AUDIENCE
This activity is intended for hematologists and other clinicians involved in the diagnosis and treatment of patients with hemophilia.

ESTIMATED TIME TO COMPLETE
The activity consists of three sessions, each of which should take approximately 1 hour to complete.

METHOD OF PARTICIPATION
There are no fees to participate in this activity. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. It is estimated that each module will take approximately 1 hour to complete. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FACULTY DISCLOSURE
The "Conflict of Interest Disclosure Policy" of Albert Einstein College of Medicine requires that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience any relationship(s) with a pharmaceutical or equipment company. Any presenter whose disclosed relationships prove to create a conflict of interest, with regard to their contribution to the activity, will not be permitted to present.

The Albert Einstein College of Medicine also requires that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience when discussing any unlabeled or investigational use of any commercial product, or device, not yet approved for use in the United States.

Presenters: Disclosures:
Patrick F. Fogarty, MD Grants/Research: Baxter, Pfizer, Biogen IDEC, CSL Behring
Consultant: Baxter, Pfizer, Biogen IDEC, Amgen, Bayer, Chugai, NovoNordisk
Susan Cutter, LCSW, MSW, MPA Consultant: CSL Behring
Susan Karp, CNS Consultant: Biogen Idec
Eric Hume, MD Has nothing to disclose.
William H. Matthai, Jr. MD Grants/Research: Johnson and Johnson
Einstein-Montefiore Center for Continuing Medical Education The Center for Continuing Medical Education (CCME) staff at Albert Einstein College of Medicine of Yeshiva University have no disclosures to report other than the following: Steven Jay Feld, or a member of his household, owns securities in Bioheart, Inc.; Chelsea Therapeutics, Inc.; Depomed and Ligand Pharmaceuticals Inc.
Henny H. Billett, MD Has nothing to disclose.
PlatformQ Health, Inc  
Randi O'Hara, Senior Program Manager Has nothing to disclose.
Alyce Kuklinski, NP, RN, Senior Medical Director Has nothing to disclose.

CONTACT INFORMATION
Please send all inquiries to: Montefiore Medical Center, CCME, 3301 Bainbridge Avenue, Bronx, New York 10467, or via phone at (718) 920-6674(718) 920-6674, or via fax to (718) 798-2336, or via email to cme@montefiore.org.

For issues with your CME Certificate, please contact OMedLive at 877-394-1306877-394-1306 or at Support@OMedLive.com

Forgot Password Click Here to Register